ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,035.69
-1.57%
Dow Jones
37,815.92
-1.49%
US Dollar vs MXN
17.1375
-0.09%
Brent Oil
85.575
-0.37%
Bitcoin
60,098.83
-0.83%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Royalty Pharma PLC (RPRX)

  7. Royalty Pharma PLC (RPRX) Noticias

RPRX Royalty Pharma PLC

27.70
-0.42 (-1.49%)
30 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Royalty Pharma PLC RPRX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.42 -1.49% 27.70 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
28.05 27.68 28.13 27.70 28.12
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
19/4/202407:15GLOBERoyalty Pharma to Announce First Quarter 2024 Financial..
17/4/202407:15GLOBERoyalty Pharma Declares Second Quarter 2024 Dividend
28/2/202415:15GLOBERoyalty Pharma to Present at TD Cowen’s 44th Annual Health..
15/2/202408:05EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
15/2/202406:33EDGAR2Form 8-K - Current report
15/2/202406:30GLOBERoyalty Pharma Reports Q4 and Full Year 2023 Results
06/2/202406:01EDGAR2Form 8-K - Current report
30/1/202415:15GLOBERoyalty Pharma To Announce Fourth Quarter And Full Year 2023..
19/1/202407:15GLOBERoyalty Pharma Announces Dividend Increase
08/1/202406:18EDGAR2Form 8-K - Current report
08/1/202406:00GLOBERoyalty Pharma Highlights Accomplishments and Provides..
03/1/202415:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202415:30EDGAR2Form 144 - Report of proposed sale of securities
29/12/202315:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/12/202315:31EDGAR2Form 8-K - Current report
27/12/202312:05EDGAR2Form 8-K - Current report
19/12/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202315:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202315:47EDGAR2Form 144 - Report of proposed sale of securities
27/11/202315:15GLOBERoyalty Pharma to Present at the Evercore ISI 6th Annual..
16/11/202316:16EDGAR2Form 8-K - Current report
16/11/202316:13EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14/11/202318:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202307:10GLOBERoyalty Pharma and Teva Collaborate to Further Accelerate..
13/11/202307:00BWTeva and Royalty Pharma Collaborate to Further Accelerate..
08/11/202308:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202306:40EDGAR2Form 8-K - Current report
08/11/202306:00GLOBERoyalty Pharma Reports Third Quarter 2023 Results
19/10/202308:29EDGAR2Form 8-K - Current report
19/10/202306:59GLOBERoyalty Pharma Announces Agreement to Purchase Up to $1.5..
16/10/202315:15GLOBERoyalty Pharma Declares Fourth Quarter 2023 Dividend
11/10/202315:15GLOBERoyalty Pharma To Announce Third Quarter 2023 Financial..
03/10/202315:15EDGAR2Form 144 - Report of proposed sale of securities
03/10/202315:15EDGAR2Form 144 - Report of proposed sale of securities
21/9/202307:25GLOBERoyalty Pharma Appoints Eric Schneider as Chief Technology..
05/9/202315:15GLOBERoyalty Pharma and Ascendis Pharma Enter Into $150 Million..
05/9/202315:01GLOBEAscendis Pharma and Royalty Pharma Enter into $150 Million..
05/9/202307:25GLOBERoyalty Pharma to Present at Upcoming Investor Conferences
24/8/202305:30GLOBERoyalty Pharma and Ferring Pharmaceuticals Enter Into US..
24/8/202300:15BWRoyalty Pharma and Ferring Pharmaceuticals Enter into US..
11/8/202316:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/8/202315:45EDGAR2Form 144 - Report of proposed sale of securities
08/8/202316:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202316:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202308:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202306:31EDGAR2Form 8-K - Current report
08/8/202306:00GLOBERoyalty Pharma Reports Second Quarter 2023 Results
18/7/202315:15GLOBERoyalty Pharma to Announce Second Quarter 2023 Financial..
17/7/202315:15GLOBERoyalty Pharma Declares Third Quarter 2023 Dividend
14/7/202317:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Su Consulta Reciente

NASDAQ
RPRX
Royalty Pharma
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados